Ergotamine Abuse. Do Patients Benefit from                 Withdrawal?

Tfelt‐Hansen, Peer; Krabbe, Annette

doi:10.1111/j.1468-2982.1981.tb00005.x

Cited by 73 publications

(51 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Later reports by Andersson [5] and Tfelt-Hansen and Krabbe [6] confirmed this pattern and also reported that recidivism to use of ergotamine with recurrence of severe rebound headache occurred in 33% to 50% of subjects withdrawn from these medications. Subsequent work identified a similar pattern in those using daily butabarbital.…”

Section: Rebound-withdrawal Headache (Medication Overuse Headache)mentioning

confidence: 69%

“…In the period from 1950 to 1980, the concept of headache related to medication overuse was developed by Peters and Horton [2], Friedman et al [3], and Kudrow [4] in America, and by Andersson [5] and TfeltHansen and Krabbe [6] in Europe. In the 1970s, debates about tension headache with secondary vascular component versus vascular headache with secondary tension component were frequently heard.…”

Section: Background Of the Diseasementioning

confidence: 99%

See 1 more Smart Citation

Chronic daily headache

Couch

2003

Curr Treat Options Neurol

View full text Add to dashboard Cite

The therapy of chronic daily headache (CDH) is complex and involves a combination of drugs, supportive psychotherapy, nondrug therapy, "tender-loving care," and "tough love." CDH is a chronic problem with exacerbations and remissions. Patients with CDH often manifest mood disorders, and recognition and treatment of these problems is a key component of success. The use of preventative antimigraine therapy is a major component of treatment of this condition. Patients with exacerbations may need judicious short courses of medications that can produce medication-overuse headache. Patients may switch to another physician to get opiates or other pain relief medications. The patient may later realize this mistake and return to the physician. Use of patient "contracts," in which the patient agrees not to take more than a prescribed amount of restricted medication or seek it elsewhere, may be helpful. In this area, there is no standard patient or standard therapeutic regimen. The treatment plan must be individualized for each patient. Taking a little extra time to talk with patients and discuss medications, procedures, and goals and objectives may pay bigger dividends in the therapeutic relationship later in the course of treatment.

show abstract

Section: Rebound-withdrawal Headache (Medication Overuse Headache)mentioning

confidence: 69%

Section: Background Of the Diseasementioning

confidence: 99%

Chronic daily headache

Couch

2003

Curr Treat Options Neurol

View full text Add to dashboard Cite

show abstract

“…The duration of chronic drug overuse was found by some authors to be a significant parameter [27][28][29]; for example, the type of analgesic abused was relevant in maintaining CDH and drug abuse [29][30][31]. On the other hand, others did not find any significant prognostic factor for long-term outcome in CDH patients [32,33].…”

Section: Discussionmentioning

confidence: 90%

Chronic daily headache: how to manage it?

Pini¹

2003

J Headache Pain

View full text Add to dashboard Cite

The role of daily analgesic use (also called abuse) in chronic daily headache (CDH) for the maintenance of chronic headache is discussed. The comprehension of the underlying mechanisms of actions is lacking mainly because of the absence of animal models. The abuse should be considered as a compulsive behavior rather than linked to the type of analgesic used and related both to "how" the drug is taken and to "what" drug is used. Moreover, there is no evidence of addictive personality in these patients, and also predictive factors for the long-term outcomes are inconsistent. In the literature specific indications are lacking for the treatment to be performed in these patients. In conclusion, the main problem for these patients is to manage their headaches, and the aim of the therapy should be to enable patients to feel in control of their migraine rather than feel that migraine or analgesic drugs control them.

show abstract

“…With regard to ergotamine withdrawal, Andersson [18] and Tfelt-Hansen and Krabbe [19] noted that there was a 33% to 50% rate of recidivism to ergotamine use in patients withdrawing from ergotamine. Diener and Dahlöf [10] and Katsarava et al [20] have suggested that cautious re-exposure to triptans may not trigger recurrent MOH.…”

Section: Medication-overuse Headachementioning

confidence: 98%

The long-term prognosis of tension-type headache

Couch

2005

Current Science Inc

View full text Add to dashboard Cite

Tension-type headache (TTH) is a very common problem that usually causes only minimal to moderate discomfort and little disability. If episodic TTH evolves to chronic TTH, then the morbidity in terms of discomfort, disability, and use of medication escalates dramatically. There are no long-term studies, but inferences can be made from population surveys. These suggest that episodic TTH occurs in 15% to 75% of the population, but 30% to 40% is the most common estimate. There is a modest increase in prevalence between the ages of 30 and 50 years and a decrease to 25% to 35% prevalence after the age of 60 years. TTH appears to remain a problem for most sufferers throughout their lives.

show abstract

Ergotamine Abuse. Do Patients Benefit from Withdrawal?

Cited by 73 publications

References 11 publications

Chronic daily headache

Chronic daily headache

Chronic daily headache: how to manage it?

The long-term prognosis of tension-type headache

Contact Info

Product

Resources

About